04.26.22 -- MIT, BioMarin Collaborate To Weigh DNA Cargo In AAV Vectors

To realize the full potential of AAV-based therapies, it is necessary to eliminate impurities in the manufacturing process that decrease the efficacy of treatments and increase their cost. A collaboration between MIT and BioMarin developed a way to quantify the light capsids in preparations of AAV-based vectors.

A biotech company that this author worked with had an expanding pipeline and needed to increase its manufacturing capacity, so single-use technologies were implemented from media prep through buff prep, to seed train and through the downstream process. The company saw a dramatic reduction of production costs.